Prostaglandin A₂ Enhances Cellular Insulin Sensitivity via a Mechanism that Involves the Orphan Nuclear Receptor NR4A3

Abstract

We have previously reported that members of the NR4A family of orphan nuclear receptors can augment insulin's ability to stimulate glucose transport in adipocytes. In the current study, we endeavored to test for an insulin-sensitizing effect in muscle cells and to identify a potential transactivator. Lentiviral constructs were used to engineer both hyperexpression and shRNA silencing of NR4A3 in C2C12 myocytes. The NR4A3 hyper-expression construct led to a significant increase in insulin-stimulated glucose transport rates in the presence of maximal insulin while the NR4A3 knock-down exhibited a significant reduction in insulin-stimulated glucose transport rates. Consistently, insulin-mediated AKT phosphorylation was increased by NR4A3 hyperexpression and decreased following shRNA NR4A3 suppression. Then, we examined effects of prostaglandin A₂ (PGA₂) on insulin action and NR4A3 transactiva-

tion. PGA₂ augmented insulin-stimulated glucose uptake in C2C12 myocytes and AKT phosphorylation after 12-h treatment, without significant effects on basal transport or basal AKT phosphorylation. More importantly, we demonstrated that PGA₂ led to a greater improvement in insulin-stimulated glucose rates in NR4A3 overexpressing C2C12 myocytes, when compared with Lac-Z controls stimulated with insulin and PGA₂. Moreover, the sensitizing effect of PGA₂ was significantly diminished in NR4A3 knockdown myocytes compared to scramble controls. These results show for the first time that: (i) PGA₂ augments insulin action in myocytes as manifested by enhanced stimulation of glucose transport and AKT phosphorylation; and (ii) the insulin sensitizing effect is dependent upon the orphan nuclear receptor NR4A3.

Supporting Information available online at http://www.thieme-connect.de/ejournals/toct/hmr

Introduction

For the past several decades, the global prevalence of Type 2 Diabetes Mellitus (T2DM) and the Metabolic Syndrome has been increasing. Insulin resistance is central to the pathogenesis of these diseases, and involves impaired insulin action in skeletal muscle. Even so, the mechanisms causing insulin resistance have not been fully elucidated, and optimal strategies for pharmacological intervention have not been developed.

Recently, there has been a growing interest in NR4A orphan nuclear receptors as potential targets for metabolic diseases. There are 3 members in NR4A family: NR4A1 (TR3, NGFI-B, N10, DHR38, NAK-1, TIS1 or Nur77), NR4A2 (HZF-3, RNR-3, TINUR, NOT or Nurr1), and NR4A3 (NORR-1, TEC, CHN or MINOR). NR4A family members differ from other nuclear receptors in that they lack the classic hydrophobic cleft for recruitment of coactivators and corepressors on their C-terminal ligand-binding domain [1]. They bind the NGFI-B response element (NBRE) and putatively activate gene expression in a ligand-independent manner [2]. NR4As are immediate early stress response genes that can be induced by a wide range of physiological signals such as inflammatory cytokines [3], prostaglandins [4], and growth factors [5]. This subgroup has also been shown to be involved in various pathological conditions, including Parkinson’s disease [6], inflammation [7], atherosclerosis [8] and cancer [9]. Furthermore, all 3 NR4A members are inducible by chronic caloric restriction in rat liver and skeletal muscle [10]. This finding is particularly interesting since both chronic and intermittent caloric restriction have been shown to enhance insulin sensitivity in numerous species [11]. Finally,
NR4A1 null mice exhibit insulin resistance in skeletal muscle and liver together with an impaired fat metabolism [12]. Our laboratory has reported that NR4A3, a member of NR4A orphan nuclear receptor family, can enhance insulin sensitivity and glucose transport stimulation in 3T3-L1 adipocytes, and is downregulated in insulin resistant or diabetic rodent models [13]. While these results suggest a potential role for NR4A3 as a therapeutic target for modulation of insulin action, it will be important to demonstrate that NR4A3 enhances insulin sensitivity in skeletal muscle, which is responsible for the bulk of insulin-mediated glucose uptake in human metabolism. It would also be imperative to show that a small molecular agonist of the orphan receptor could produce an increase in insulin action.

In our current study, we have examined whether alterations in NR4A3 expression affect insulin sensitivity in C2C12 muscle cells. Furthermore, we have studied prostaglandin A2 (PGA2) as a potential transactivator of NR4A3 in muscle cells following the report by Kagaya et al. [4] showing that PGA2 enhances NR4A3-dependent transcriptional activity. PGA2 belongs to the cyclopentanone prostaglandin family, which was thought to exert potent and specific regulatory effects on protein activities, as extensively reviewed by Strauss et al. [14]. This transactivation was largely dependent on a direct physical interaction between PGA2 and the ligand binding domain of NR4A3. We have shown for the first time that PGA2 exerts an insulin-sensitizing effect, and that this action is dependent upon NR4A3. These results are consistent with our previous report in adipocytes [13], and confirmed the importance of NR4A3 in the regulation of insulin action in skeletal muscle cells. Further, our findings highlight the potential role of PGA2 or other small molecule agonists of NR4A3 as therapeutic modulators of insulin action.

Materials and Methods

Reagents

Mouse C2C12 myoblast cells were purchased from American Type Culture Collection (Manassas, VA, USA). Tissue culture media were products of Invitrogen. NR4A3 antibody (Catalogue No: PP-H7833-00) was purchased from R & D Systems (MN, USA), and actin antibody (Catalogue No: sc-130065) was from Santa Cruz (CA, USA), 2-deoxy-D-[3H]- and L-[1-3H]glucose were purchased from Amersham Biosciences. All other reagents were purchased from Sigma, unless specified. Unless specified, all other antibodies were purchased from Cell Signaling.

Cell culture and stimulation

The C2C12 are maintained as growing myoblasts in Dulbecco’s minimal essential medium (DMEM, Mediatech) containing 1 g/l glucose, and 10% fetal bovine serum (GIBCO). Mass cultures reached 70–80% confluence within 48 h. Differentiation of C2C12 myoblasts was induced by reducing the serum concentration (2% horse serum, Hy-Clone). The cultures were supplied with 2% horse serum DMEM daily thereafter, and then serum-starved overnight preceding experiments.

Recombinant lentiviruses and lentiviral-transduced cell lines

Lentiviral-transduced NR4A3 overexpression and shRNA construct cloning procedures have been described in our previous report [13]. Briefly, the full-length human NR4A3 cDNA coding sequence and a V5 epitope tag were cloned into a Vira-Power-CMV vector (Invitrogen). The NR4A3 construct and a control LacZ gene plasmid were transfected into HEK293 cells. Western blots were performed to confirm successful transfection, and infectious virus particles were produced according to the manufacturer’s protocol (Invitrogen). To establish stable C2C12 myocytes that overexpress NR4A3 or LacZ genes, recombinant NR4A3 or LacZ lentiviral stocks were used to infect C2C12 myoblasts with Polybrene (Specialty Media, Phillipsburg, NJ, USA) at a final concentration of 6 μg/ml. Seventy two h after transfection, cells were placed under blasticidin selection (30 μg/ml) for 20 days. Western blot analyses were performed to test for stable NR4A3 or LacZ gene expression after antibiotic selection.

Lentiviral based endogenous NR4A3 gene hypoexpression

Three shRNA hairpin oligonucleotides (sense 5’-CAC CGC TGT TTG TCC TCA GAC TTT CCG AAG AAA ACA ACA GC-3’; antisense 5’-AAA AGC TGT TTG TCC GAC ATC CAA ACA GC-3′; sense 5’-CAC CGC TGA GCA ACA ATT CCG AAT AAT TGC ACA TGC TCA GC-3’; antisense 5’-AAA AGC TGA GCA ACA ATT CCG AAT AAT TGC ACA TGC TCA GC-3′; sense 5’-CAC CGC TGT TTG TCC TCA GAC TTT CCG AAG AAA ACA ACA GC-3′; antisense 5’-AAA AGC TGA GCA ACA ATT CCG AAT AAT TGC ACA TGC TCA GC-3′; sense 5’-CAC CGC TGT TTG TCC TCA GAC TTT CCG AAG AAA ACA ACA GC-3′; antisense 5’-AAA AGC TGA GCA ACA ATT CCG AAT AAT TGC ACA TGC TCA GC-3′) that are complementary to the mouse NR4A3 gene coding sequences were synthesized by Integrated DNA Technologies (Corallville, IA, USA), and subcloned into the pENTR™/U6 lentiviral vectors (Invitrogen) to create the NR4A3 shRNA constructs following the manufacturer’s instructions. Three specific target sequences in the gene coding region for the knockdown experiments were 5’-GCT GGT GTT CCT CAG ACT TTC-3’, 5’-GCT GGT GTT CCT CAG ACT TTC-3’, and 5’-GCT GGT GTT CCT CAG ACT TTC-3’ for the 3 synthesized short oligonucleotides. The recombinant shRNA-NR4A3 lentiviral plasmid or control scramble construct was transfected into HEK293 cells to generate lentiviruses. Thereafter, shRNA lentiviruses were transfected into C2C12 myoblasts to generate cell lines exhibiting NR4A3 suppression in parallel with the scramble control cell lines. Stable knockdown cell lines were selected under the same conditions as the NR4A3 overexpression cell lines described above.

Westernblot analyses

Myocytes were treated with cell lysis buffer (1× phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing freshly added protease inhibitor mixture (Sigma). Fifty micrograms of protein per lane and known molecular weight markers from Bio-Rad were separated by SDS-polyacrylamide gel electrophoresis. Proteins were electrophoretically transferred onto nitrocellulose membranes and incubated overnight at 4 °C with blocking solution (5% nonfat milk in Tris-buffered saline). The blocked membranes were incubated with Akt or phospho-Akt antibodies (Zee Biologic) and then peroxidase-conjugated second antibody (1:1 000 or 1:5 000 dilution with 1% nonfat milk in Tris-buffered saline (TBS)) for 1 h each for each room temperature and washed 3 times each with TBS buffer containing 0.1% Tween 20 for 15 min at room temperature with rocking. Immunodetection analyses were performed using the Enhance Chemiluminescence Kit (PerkinElmer Life Sciences). Typical data were shown after similar results were obtained in 3 or more independent experiments.
Experimental results are shown as the mean±S.D. Statistical analyses were performed by unpaired Students t-test or 2-way ANOVA assuming unequal variance unless otherwise indicated. Significance was defined as *p < 0.05, or **p<0.01.

Results

Our group has shown that NR4A3 is induced during differentiation of 3T3-L1 adipocytes [13]. In C2C12 myocytes, we now similarly observed that NR4A3 expression is induced during differentiation (Fig. 1). The increments in NR4A3 protein expression accompanied both the histological evidence of muscle cell differentiation (Fig. S1A, S1B) and the induction of myosin heavy chain protein (Fig. S1C). In order to elucidate the role of NR4A3 in insulin action in C2C12 myocytes, we made lentiviral constructs for both NR4A3 stable hyperexpression and knockdown, together with transduced LacZ and scramble control cells. The hyperexpression construct results in approximately doubled NR4A3 protein expression compared to LacZ control (Fig. 2A, Fig. S2A), and the knockdown construct decreases NR4A3 protein by approximately 75% compared to scramble control (Fig. 2B, S2B, S2C). It is important to note that NR4A1 and NR4A2 protein expression was not changed by NR4A3 overexpression or knockdown (Fig. S2D). In addition, our initial observation suggested that the extent and temporal progression of muscle cell differentiation were not affected by lentivirus-mediated NR4A3 hyperexpression, nor by shRNA-mediated NR4A3 repression and this result was further confirmed with unchanged myosin heavy chain expression or cell morphology upon NR4A3 overexpression or knockdown (Fig. S2E, S2F). Thus, NR4A3 does not appear to influence differentiation from a histological or biochemical perspective.

Even so, our data did indicate that NR4A3 was involved in achieving a fully insulin-responsive functional phenotype in myocytes as we had previously demonstrated in adipocytes [13]. As a consequence of NR4A3 hyperexpression, we observed a significant elevation in insulin-stimulated glucose transport in C2C12 myocytes compared to LacZ controls in a concentration dependent manner (Fig. 3A, S3A), while no significant effects on basal glucose transport were observed. We also found that NR4A3 hyperexpression significantly enhanced insulin-mediated Akt/PKB ser473 phosphorylation (Figs. 3B, c, S3B, S3C), without affecting GSK-3β ser9 phosphorylation (Fig. S3D, S3E). Conversely, NR4A3 knockdown led to a state of relative insulin resistance with a significant decline in insulin’s ability to stimulate glucose transport activity (Fig. 4a, S4A) and Akt/PKB phosphorylation (Fig. 4b, c, S4B, S4C). Again, no significant basal glucose transport change was observed after NR4A3 silencing.

A previous report indicated that PGAs is able to bind NR4A3 and activate NR4A3-dependent transcription [4]. Based on this discovery and the fact that NR4A3 regulates insulin action and downstream signaling, we hypothesized that PGAs and other cyclopentenone prostaglandins would also increase insulin sensitivity through NR4A3 agonism. PGA2 did significantly enhance insulin sensitivity without altering basal glucose uptake in wild-type C2C12 myocytes (Fig. S5a, p<0.01). We also observed increased Akt/PKB ser473 phosphorylation (Fig. S5b, c) when cells were incubated in the presence of both insulin and PGA2, with no changes in GSK3β phosphorylation (Fig. S4D, S4E).
However, GLUT4 protein expression seemed to be unchanged after NR4A3 hyperexpression, knockdown or PGA2 treatment, which indicates that GLUT4 expression change was not involved in NR4A3- or PGA2-mediated insulin sensitization (Fig. S5A, S5B). Interestingly, the insulin sensitization effect of PGA2 could not be attributed to decreased insulin EC50. Our data suggested that PGA2 enhances maximal insulin action (Fig. 5d). Additional data indicated that the insulin sensitization effect of PGA2 is both time and concentration related, with a 12-h incubation in 10 μM PGA2 producing the maximal increase in insulin-stimulated glucose transport (Fig. 6a, b, respectively).

In wild-type C2C12 cells, we did not observe any effects of PGE2 or PGA2-isoprostanes on insulin-stimulated glucose transport (data not shown). The PGA2 metabolite 15-deoxy-12,14-PGA2 increased mean insulin-stimulated glucose transport, but this effect did not reach statistical significance (data not shown).
We hypothesized that the insulin-sensitizing effect of PGA2 was mediated via NR4A3 in muscle cells. To address this question, NR4A3 knockdown and scramble control C2C12 myocyte lines were pretreated with or without PGA2, and then acutely stimulated by insulin. As expected, NR4A3 knockdown not only reduced insulin-mediated glucose transport but also abrogated the insulin sensitizing effect of PGA2 (Fig. 7a). Likewise, NR4A3 hyperexpression significantly enhanced insulin-stimulated glucose transport in wild type cells and the effect of with PGA2 to improve insulin sensitivity (Fig. 7b). Taken together, we were able to conclude that NR4A3 is required for the insulin sensitizing effect of PGA2.

**Discussion**

NR4A nuclear receptors appear to exert diverse influences on cell physiology. In cultured adipocytes, we had previously shown that NR4A3 overexpression increased insulin-stimulated glucose transport rates by increasing GLUT4 translocation, with no change in total cellular GLUT4 content. The data presented in this report extend our previous findings to skeletal muscle. As observed in adipocytes, NR4A3 overexpression significantly enhances insulin-stimulated glucose transport in C2C12 muscle cells, while shRNA suppression of NR4A3 reduces insulin-stimulated glucose transport.

NR4A family members can be functionally redundant in specific instances. NR4A3 and NR4A1 have been implicated in metabolic regulation in liver, and adenoviral overexpression of NR4A3 or NR4A1 in primary mouse hepatocytes increases expression of both fructose bisphosphatase-2 (a.k.a. phosphofructokinase 2) and enolase-3 and increases pyruvate-derived glucose production [17]. With respect to metabolism in skeletal muscle, NR4A3 has not been as well studied; however, when the current data are examined in light of previous publications concerning NR4A1, it is clear that both NR4A family members can overlap in their metabolic effects. Importantly, overexpression of NR4A1 in C2C12 cells enhances basal glucose transport, with no change in GLUT1 expression [18]. It is also interesting to note that overexpression of NR4A1 increases expression of GLUT4, phosphofructokinase, and glycogen phosphorylase in C2C12 cells and in rat muscle [18]. Furthermore, NR4A1 null mice are no different from wild-type mice when fed with standard diet, but are more susceptible to metabolic dysfunction when maintained on high
fat diet; thus, when fed with high fat diet, NR4A1/−/− mice become more obese and insulin resistant, with impaired insulin signaling in skeletal muscle driving these changes. Interestingly, NR4A1 knockout mice also displayed increased intramyocellular lipid content and hepatic steatosis, but maintained normal hepatic insulin sensitivity [12]. These data, along with ours, suggest that NR4A3 and NR4A1 modulate cell-type specific metabolic functions, and enhance metabolic functions and insulin actions in muscle. The current effects on insulin action occurred as a result of specific modulation of NR4A3 expression, without changes in NR4A1, indicating that the induced hyperexpression and suppression of NR4A3 predominate in the modulation of insulin sensitivity under these experimental conditions. Cyclopentenone prostaglandins are known to modulate the transcriptional activity of other nuclear receptors, including PPAR-γ, NF-κB, AP-1, Nrf2, HIF1-α [19], and estrogen receptor-α [20]. These prostaglandins include PGA₂, PGA₁, and PGJ₂, and are formed by dehydration of the cyclopentane rings of PGE₂, PGE₁, and PGD₂ respectively, resulting in an unsaturated carbonyl group that is electrophilic and reactive [14,21]. Unlike receptor-binding prostaglandins, cyclopentenone prostaglandins covalently bind specific target proteins, and these adducts result from covalent interaction between protein cysteine thiols and the α,β-unsaturated carbonyl moiety in the cyclopentenones [20]. The reaction between the electrophilic carbons and their target proteins is nonpromiscuous, highly specific, and can alter protein activities [14,21–24]. Because the ligand-binding domain of NR4A proteins lacks a hydrophobic cleft, it was thought that these receptors may function constitutively in the absence of ligand. However, Kagaya et al. have identified PGA₂ as a specific transactivator of NR4A3 [4]. This group showed that PGA₂ activated NR4A3-dependent transcription, and that this PGA₂ action was dependent upon interaction with the NR4A3 ligand binding domain [4]. Based on these results, we hypothesized that PGA₂ would improve skeletal muscle insulin sensitivity through transactivation of NR4A3.

The improvement in insulin action due to the interaction between a prostanoid (PGA₂) and a nuclear transcription factor (NR4A3) is analogous to the effects of PGJ₂ metabolites interacting with PPARγ. PGJ₂ was discovered as a dehydration product of PGD₂ in studies assessing their antineoplastic properties [25], and can undergo albumin-assisted catalysis to Δ12-15-PGJ₂ and 15-deoxy-Δ12,14-PGJ₂ [26]. In 1995, 15-deoxy-Δ12,14-PGJ₂ was found to enhance insulin action as a high affinity ligand and agonist for PPARγ [27,28]. In light of the current results, it is important to note that PGA₂ is not known to interact with PPARγ [14]. Kagaya et al. have comprehensively screened a large number of

Zhu X et al. NR4A3-dependent Effects of PGA₂ on Insulin Sensitivity... Horm Metab Res 2013; 45: 213–220
naturally occurring arachidonic acid and glycerolipid metabolites from the KEGG database, and found that only PGA$_2$ and PGA$_3$ have the unique ability to activate NR4A3-dependent transcription using a GAL4-based reporter system [4]. Furthermore, using mutational analyses and a Biacore resonance sensor, they demonstrated that PGA$_2$ action was dependent upon binding of PGA$_2$ to the ligand binding domain of NR4A3. Even so, the possible biochemical mechanism by which PGA$_2$ interacts with NR4A3 in muscle cells remains unclear even though our data indicate that NR4A3 is necessary for the insulin-sensitizing effect of PGA$_2$.

We should admit that it still remains unclear how NR4A3 and PGA$_2$ treatment augment insulin action in C2C12 myocyte culture system. Our previous data from 3T3-L1 adipocytes suggested that GLUT4 translocation but not expression may be involved in NR4A3-mediated insulin sensitivity augmentation in 3T3-L1 cells. However, in C2C12 myocytes it may be different since Tortorella et al. reported that C2C12 myocytes lacks GLUT4 translocation machinery which exists in adipose tissue [29]. Further studies showed that GLUT4 translocation may not play a major role in insulin action in C2C12 myocytes and a modified glucose uptake assay protocol should be used in this system [16]. These observations, together with our data, suggested that an underlying mechanism other than GLUT4 translocation may be involved in NR4A3- and PGA$_2$-mediated insulin sensitization in C2C12 myocytes. In the future animal models such as skeletal muscle-specific NR4A3 knockout and transgenic mice would likely provide valuable insight regarding the in vivo significance of NR4A3 as a modulator of glucose metabolism and insulin sensitivity.

In closing, our results demonstrate that NR4A3 mediates an increase in insulin-stimulated glucose transport and AKT phosphorylation in muscle cells. It seems to be an attractive pharmacological target for the modulation of insulin sensitivity, and diseases characterized by insulin resistance such as Type 2 Diabetes and the Metabolic Syndrome. We have also shown for the first time that PGA$_2$ enhances insulin sensitivity, and this occurs via a mechanism involving NR4A3. This provides proof-of-principle that a small molecule mediator can have an insulin-sensitizing effect through an interaction with NR4A3.

References
2 Davis IJ, Lau LF. Endocrine and neurogenic regulation of the orphan nuclear receptors Nur77 and Nur-1 in the adrenal glands. Mol Cell Biol 1994; 14: 3460–3483
3 Borghaei RC, Rawlings Pl Jr, Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum 1998; 41: 1398–1406
5 Hazel TG, Nathans D, Lau LF. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc Natl Acad Sci USA 1988; 85: 8444–8448
7 Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol 2006; 20: 786–794
10 Oita BC, Mazzetti DJ, Lim FL, Powell JR, Merry BJ. Whole-genome microarray analysis identifies up-regulation of Nr4a1 nuclear receptors in muscle and liver from diet-restricted rats. Mech Ageing Dev 2009; 130: 240–247
11 Fontana I, Klein S, Holloszy JO. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age (Dordr) 2010; 32: 97–108
22 Oh JY, Giles N, Landar A, Darley-Urmson V. Accumulation of 15-deoxy- delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction. Biochem J 2008; 411: 297–306

Acknowledgements

This work was supported from grants from the National Institutes of Health (DK-083562, DK-038764, HL-055782 to W.T.G.), the Merit Review program of the Department of Veterans Affairs (W.T.G.), and the American Diabetes Association (Y.F.). We gratefully acknowledge the support of the research core facilities of the UAB Diabetes Research and Training Center (P60-DK079626) and the UAB Nutrition and Obesity Research Center (P30-DK56336).

Conflict of Interest

The authors have no conflict of interest.

Zhu X et al. NR4A3-dependent Effects of PGA$_2$ on Insulin Sensitivity ... Horm Metab Res 2013; 45: 213–220